Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

NCT01027598 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

202

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Pazopanib
DRUG: Erlotinib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]